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Background: The US Joint National Committee (JNC) on
Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure issues guidelines on the optimal ﬁrst-
line drug therapy in treating hypertension. Despite broad
dissemination of these guidelines, prescribing practices
have long remained discrepant with recommendations.
The purpose of this study was to examine the role of
insurance type in the selection of drugs for hypertension
treatment in light of the JNC guidelines.
Methods: Subjects were derived from the 1996 Medical
Expenditures Panel Survey who had a diagnosis of essen-
tial hypertension and who were prescribed a diuretic,
beta-blocker, calcium channel blocker (CCB), or ACE
inhibitor (ACEI) as monotherapy. Using the nationally
representative sample, this study presents the ﬁrst esti-
mates of the impact of insurance policies on the choice of
antihypertensive drugs while controlling for predisposing,
enabling, and need variables in the context of a logistic
health-care utilization model.
Results: Nationally in 1996, more than twice as many
subjects (7.3 million) were taking ACEIs or CCBs com-
pared to diuretics or beta-blockers (3.1 million) as the
ﬁrst-line drug therapy, a sharp contrast to the JNC guide-
lines. Patients with health maintenance organization
(HMO) insurance were much less likely than fee for
service (FFS) patients to follow the JNC guidelines in this
respect (odds ratio 0.50, P < .01), controlling for all other
factors. Individuals with all other public insurance and
no insurance were not statistically different from the FFS
group in the use of the study drugs. Other signiﬁcant
factors in the regression model were being of African
American descent, being unmarried, having higher out-
of-pocket payment, being in excellent physical health,
having diabetes, and being diagnosed with essential
hypertension after 1988. Each was associated with a
decreased likelihood of following the JNC recommenda-
tions for the use of diuretics or beta-blockers.
Conclusions: After controlling for other predisposing,
enabling, and need variables, patients who had HMO
coverage were signiﬁcantly more likely than FFS patients
to receive ACEIs or CCBs. Given a popular public per-
ception of HMOs being most cost conscious in providing
health care, further research is needed to understand why
prescribing patterns associated with HMOs have poorly
followed the JNC recommendations.
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ABSTRACT
Introduction
Hypertension is associated with increased risk of
stroke, myocardial infarction, atrial ﬁbrillation,
heart failure, peripheral vascular disease, and renal
disease [1,2]. Hypertension has become a major
public health threat to Americans, both medically
and economically. About 50 million Americans, or
25% of American adults, have high blood pressure
[3]. The total cost of antihypertensive treatment
was estimated to be as high as $40 billion in the
United States in 1999. The indirect cost of hyper-
tension is even more striking, including the cost of
increased mortality and morbidity from coronary
heart disease, stroke, and congestive heart failure
that occurs in untreated or undertreated hyperten-
sive patients.
Drug therapy has played a key role in hyperten-
sion control and treatment, with six major classes
of antihypertensive drugs available: diuretics, 
beta-blockers, calcium channel blockers (CCBs),
angiotensin-converting enzyme inhibitors (ACEIs),
adrenergic inhibitors, and angiotensin II receptor
blockers [4,5]. In the United States, the Joint
National Committee (JNC) on Prevention, Detec-
tion, Evaluation, and Treatment of High Blood
Pressure issues a consensus review report every four
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to ﬁve years that includes stepped therapy guide-
lines for clinicians in the management and treat-
ment of hypertension. The report, based on the
most current clinical evidence at the time, has
become a respected standard for the initial evalua-
tion and treatment of hypertension. The history of
JNC recommendations for hypertension is pre-
sented in Table 1.
Since 1977, the JNC reports have consistently
recommended diuretics, and since 1984, diuretics 
or beta-blockers as the ﬁrst-line drug treatment for
uncomplicated hypertension [4,6–10]. Beginning in
the early 1980s, when ACEIs and CCBs became
available, these two drugs quickly became widely
used antihypertensive agents, coupled with diuret-
ics and beta-blockers. Based on the available evi-
dence on similarities in short-term clinical efﬁcacy,
the 1988 JNC Report IV added both ACEIs and
CCBs to diuretics and beta-blockers to its recom-
mended list of ﬁrst line therapy drugs [9].
In the 1990s, several studies were carried out that
indicated an association of diuretics and beta-
blockers with a decreased risk of cardiovascular
morbidity and mortality in clinical trials [11–15].
For example, a prospective, randomized, and
double-blind intervention by Dahlof et al. [13]
demonstrated a signiﬁcant effect of three beta-
blockers (atenolol, pindolol, and metoprolol) and
two diuretics (hydrochlorothiazide and amiloride)
on the reduction of stroke mortality and morbidity
among a Swedish population cohort aged 70–84
years, compared to placebo. The Systolic Hyper-
tension in the Elderly Program [11] study demon-
strated that the 5-year total incidence of stroke was
5.2 per 100 participants in treatment group with
diuretics and beta-blockers compared to 8.2 per
100 for the placebo group, with a relative risk of
0.64 (P = .0003).
A meta-analysis of by Psaty and colleagues [15]
of 18 long-term randomized trials also showed that
diuretics and beta-blockers were more effective
compared to the placebo, for major disease end
points including the incidence of stroke and con-
gestive heart failure, as well as coronary disease and
total mortality. In contrast, there was little clinical
trial evidence available indicating comparable long-
term outcome effect of ACEIs and CCBs [16]. As 
a result, the following JNC guidelines in 1993 and
1997 recommended only diuretics and beta-
blockers as the ﬁrst-line therapy [4,10]. More
recently reported trials (since JNC VI) offer afﬁr-
mative evidence that diuretics and beta-blockers are
at least as effective in reducing overall morbid-
ity/mortality as other agents [17].
In addition, cost data also favored diuretics and
beta-blockers over ACEIs and CCBs. A cost-
minimization study by Pearce et al. [18] docu-
mented that the cost of medication treatment was
much lower with diuretics or beta-blockers than
with ACEIs or CCBs. Furthermore, Edelson and
colleagues [19] estimated the cost-effectiveness of
various initial monotherapies for mild to moderate
hypertension for 20 years (1990–2010). Using the
Coronary Heart Disease Policy Model, they found
that the dollar cost per year of life saved was higher
for an ACEI (captopril) and a CCB (nifedipine) than
for a diuretic (hydrochlorothiazide) or beta-blocker
(propranolol). More speciﬁcally, their simulation
indicated that the cost per year of life saved was
$72,100 for captopril (ACEI) and $31,600 for
nifedipine (CCB), compared to $16,400 for
hydrochlorothiazide and $10,900 for propranolol
hydrochloride.
Despite the consistent JNC recommendations
and cost advantages of diuretics and beta-blockers,
medical practices in the United States have
remained a sharp contrast [20–22]. For example, in
the most recent study of antihypertensive drugs in
retail channels in the United States, the book by
Kaplan and Lieberman [5] showed a sustained trend
of increased use of ACEIs and CCBs ever since
1986. In the meantime, the use of diuretics and
beta-blockers continued to decrease. Beginning in
the early 1990s, the total number of prescriptions
for CCBs and ACEIs exceeded the number of pre-
scriptions for beta-blockers.
Table 1 The history of JNC recommendations for hypertension
JNC Recommendation Reason
I (1977) Diuretics Established the efﬁcacy of diuretics for hypertension in 1970s.
II (1980) Diuretics Same as above.
III (1984) Diuretics and beta-blockers Established efﬁcacy of both for hypertension.
IV (1988) Diuretics, beta-blockers,ACEIs, and CCBs ACEIs and CCBs : new drugs in 1980s.
established efﬁcacy some concerns about the safety of diuretic therapy
and the side effects of diuretics and beta-blockers.
V (1993) Diuretics and beta-blockers Only diuretics and beta-blockers have been shown to reduce mortality and
morbidity.
VI (1997) Diuretics and beta-blockers Same as above.
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Some previous studies offered explanations as to
why prescribing patterns remain persistently dis-
crepant with the JNC guidelines. For instance, one
possibility is that physicians and patients may seek
to avoid side effects such as sexual dysfunction
associated with the use of beta-blockers [23,24]
and, to a lesser degree, with diuretics [25]. It is also
possible that physicians may be reluctant to change
the drug therapy for patients with well-controlled
blood pressure [26], despite new evidence that beta-
blockers and diuretics save lives. The novelty of
ACEIs or CCBs might be another factor contribut-
ing to their increased use [22]. Moreover, the impact
of pharmaceutical advertisements for new agents
might be a factor [21]. Some studies also showed
an association between patterns of antihypertensive
drug use and demographic factors such as age and
sex [27–29].
Based on our literature, however, no study has
analyzed the impact of insurance on the choice of
antihypertensive drug agents using a national data-
base. Yet the importance of insurance to the overall
use of antihypertensive drugs has been well docu-
mented in some previous studies [30–33]. For
example, Ahluwalia and colleagues [31] found that
patients with Medicaid coverage were signiﬁcantly
more likely than the uninsured to use antihyperten-
sive medications. In a recent study using the 1995
Medicare Current Beneﬁciary Survey data, Blustein
[32] demonstrated that drug coverage increased the
likelihood of patient access to all classes of antihy-
pertensive drugs. Adams and colleagues [30] further
compared the effects of different types of coverage
on the use of all these drugs, suggesting that state-
and employer-sponsored drug coverage increased
the consumption of all antihypertensive drugs.
As suggested in previous studies, if insurance
status indeed does have impact on the overall access
to antihypertensive drugs as a whole, a relevant
policy question is warranted as to whether insur-
ance type also plays a role in shaping the prescrib-
ing patterns of antihypertensive agents in contrast
with the recent JNC guidelines V (1993) and VI
(1997), both recommending the use of beta-
blockers and diuretics as the ﬁrst-line therapy for
patients with essential hypertension. This study is
the ﬁrst attempt to investigate this issue using the
1996 Medical Expenditures Panel Survey (MEPS)
national database.
Methods
This is a retrospective cross-sectional study
designed to test whether and how the types of insur-
ance are associated with the choice of antihyper-
tensive drugs using the 1996 MEPS data. Speciﬁ-
cally, we test if the likelihood of using diuretics or
beta-blockers versus ACEIs or CCBs was associated
with a patient’s health insurance after controlling
for other factors that may contribute to the treat-
ment selection.
Data
The MEPS database is designed to provide repre-
sentative estimates of health-care use, expenditures,
sources of payment, and insurance coverage at the
national level for a sample of the noninstitutional-
ized US population. It is cosponsored by the Agency
for Healthcare Research and Quality and the
National Center for Health Statistics. The MEPS
data are collected from each household by using
computer-assisted personal interviewing technol-
ogy, and this series of data collection is launched
each subsequent year on a new sample. All of these
surveys yield comprehensive data that provide
national estimates of the level and distribution 
of health-care use and expenditures. This study
obtains empirical estimates using a core component
ﬁle of MEPS (HC) that includes the follows subﬁles:
1. HC012: 1996 Full Year Consolidated Data File;
2. HC012s1: Update of 1996 Prescribed Medicine
Expenditure Variables;
3. HC006R: 1996 Medical Conditions;
4. HC010A: 1996 Prescribed Medicines File
(updated on March 16, 2001).
The HC012 ﬁle contains one record for each of
the 22,601 representative sample persons from 
the Household Component of the 1996 Panel of the
MEPS. This count includes all household survey
respondents who resided in eligible responding
households. The HC010A ﬁle contains 147,308
prescribed medicine records. Each record represents
one household-reported prescribed medicine that
was purchased or obtained during the year 1996,
and each record contains medical conditions asso-
ciated with the prescribed medicine.
Study Population
The study population was extracted from the 1996
MEPS as a representative sample of the US adult
population with essential hypertension. Patients 
eligible for the study were those aged 18 years or
above with a recorded disease condition of hyper-
tension coded as ICD-9-CM “401.x” and who
received an antihypertensive drug at least once in
1996. We excluded those who received other less
commonly used classes of antihypertensive drugs,
including adrenergic inhibitors, angiotensin II
receptor blockers, or combined treatment with any
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two classes of antihypertensive drug. To reduce
“crossover effect,” patients with concomitant use 
of more than one drug in each of the four drug
groups were also excluded. Moreover, we excluded
patients with missing values for the variables of
interest and those with a weighting index of 0 in the
database.
Main Variables
To study whether the choice of hypertensive drug
use was a function of insurance status, we deﬁned
the main outcome variable to be dichotomous, dif-
ferentiating the study population into two groups:
1) patients using diuretics or beta-blockers, and 2)
those using ACEIs or CCBs. We developed a com-
prehensive list of the antihypertensive drugs in these
classes, including all generic and brand names
according to the following sources: JNC VI [4],
Clinical Hypertension [5], Hypertension Manage-
ment: Clinical Pathways, Guidelines, and Patient
Education [34], Drug Facts and Comparisons [35],
Clinical Pharmacology 2000 [36], and Drug Topics
Red Book [37].
Following the seminal work on health service uti-
lization model by Andersen and colleagues [38], we
categorized explanatory variables potentially asso-
ciated with choice of antihypertensive drug into
three groups. Variables used in the multivariate
models were limited to those available in the 1996
MEPS database:
1. Predisposing variables: age, race, gender, edu-
cation, employment status, and marital status;
2. Enabling variables: insurance status, income,
metropolitan statistical area (MSA), and census
region;
3. Need variables: physical health status, mental
health status, functional limitations, comor-
bidities, and diagnosed year.
As a focus of the study, the insurance status was
categorized as follows:
1. HMOs, including Medicare HMOs, Medicaid
and other public HMOs, private HMOs
(private insurance with gatekeeper features);
2. Fee-for-services (FFS), including Medicare FFS,
Medicaid and other public FFS, and private
FFS;
3. Any other public plans, except Medicare, Med-
icaid, and some other public coverage that pro-
vides hospital/physician insurance;
4. No insurance.
To control for a possible impact of changes in
guidelines on the initiation of a drug therapy, we
also deﬁned three dummy variables for those being
diagnosed and treated before 1988, between 1988
and 1992, and beginning in 1993, respectively.
Using the ﬁrst period as a reference, the model thus
included two-time dummy variables when estimat-
ing the insurance effect. Detailed deﬁnitions of all
other explanatory variables are provided in Table 2.
Results
The empirical estimation of insurance impact on the
choice of antihypertensive drugs was conducted in
a logistic model analysis using SAS (Version 8.0,
2001) and STATA (Version 6, 2001) statistical soft-
ware. Estimates presented in the following text were
weighted to reﬂect the US adult population with
essential hypertension. Unless stated, only the dif-
ferences that were signiﬁcant at the level of .05 or
lower (P < .01) are reported here.
Descriptive Analysis
In the initial sample, there were a total of 2199 rep-
resentative patients identiﬁed with essential hyper-
tension and using antihypertensive drugs in the
1996 MEPS data. After applying the national
weighting index and exclusion/inclusion criteria,
the ﬁnal study sample included 814 patients with
population weight, representing a total of 10.4
million noninstitutionalized in the United States
with essential hypertension. Of them, 7.3 million
patients used only ACEIs or CCBs, and 3.1 million
patients used only diuretics or beta-blockers. Com-
paring the two drug groups, subjects were similar
in most baseline characteristics as indicated in 
Table 3.
Explanatory Analysis
Results of the multivariate logistic regression analy-
sis were estimated based on the weighted of the 10.4
million population in the United States who took a
diuretic, beta-blocker, CCB, or ACEI as monother-
apy (Table 4). We ﬁrst highlight the insurance effect
from the set of enabling variables in the model.
Holding all other covariates constant, patients with
HMO insurance were much less likely than FFS
patients to use diuretics or beta-blockers as recom-
mended by the JNC guidelines (odds ratio [OR]
0.50, 95% CI 0.32–0.77, P < .01). Individuals with
all other public insurance and no insurance were
not statistically different from the FFS group in the
likelihood of choosing diuretics or beta-blockers
versus the alternative drug classes.
We also found an association between higher
out-of-pocket payments and greater use of CCBs or
ACEIs (P < .05). None of the other enabling vari-
ables including income, residential location accord-
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ing to MSAs, and four census regions were associ-
ated with the choice of alternative antihypertensive
drug classes.
As for predisposing factors, when other con-
founders were controlled, African American
patients were less likely to use diuretics or beta-
blockers compared to white patients (OR 0.58,
95% CI 0.35–0.96, P < .05). Compared to non-
married patients, married patients were 92% more
likely to use diuretics or beta-blockers (OR 1.92,
95% CI 1.30–2.84, P < .01).
Among need variables, statistically signiﬁcant
predictors included physical health status, comor-
bidities, and diagnosed year. Compared to patients
in fair or poor physical health status, patients in
excellent or very good physical health status were
less likely to use diuretics or beta-blockers (OR
0.465, 95% CI 0.275–0.788, P < .01). Patients with
a diabetes comorbidity were less likely to use di-
uretics or beta-blockers (OR 0.343, 95% CI
0.199–0.592, P<.01), compared to patients without
comorbidities.
Table 2 Deﬁnition of variables
Variable Deﬁnition
Predisposing factors
Age Continuous variable
Race White = reference
African American DV* = 1 for African American; 0 otherwise
Other† DV = 1 for other races; 0 otherwise
Sex
Male DV =1 for male; 0 for female
Education No degree = reference
College degree or higher DV = 1 for ≥ college degrees; 0 otherwise
Other‡ DV = 1 for = other degrees; 0 otherwise
Employment status
Employed DV =1 for employed; 0 for nonemployed
Marital status
Married DV = 1 for married; 0 nonmarried
Enabling factors
Insurance status FFS = reference
HMO DV = 1 for HMO; 0 otherwise
Other public DV = 1 for Other public; 0 otherwise
Uninsured DV = 1 for uninsured ; 0 otherwise
Annual income ($) < 10,000 = reference
10,000–14,999 DV = 1 for income between 10,000 and 14,999; 0 otherwise
15,000–29,999 DV = 1 for income between 15,000 and 29,999; 0 otherwise
≥ 30,000 DV = 1 for income ≥ 30,000; 0 otherwise
MSA
Yes DV =1 for living in metropolitan statistical area; 0 otherwise
Census region Midwest = reference
Northeast DV = 1 for northeast; 0 otherwise
South DV = 1 for south; 0 otherwise
West DV = 1 for west; 0 otherwise
Total out of pocket for Total self/family payment for RX in 1996
antihypertensive drugs
Need factors
Perceived health status Fair or poor = reference
Excellent/very good DV = 1 for excellent or very good health status; 0 otherwise
Good DV = 1 for good health status; 0 otherwise
Perceived mental health status Fair or poor = reference
Excellent/very good DV = 1 for excellent or very good mental health status; 0 otherwise
Good DV = 1 for good mental health status; 0 otherwise
Limitations in daily life The number of limitations in daily life
Comorbidities
Diabetes DV = 1 for pts with diabetes (ICD 9 CM: 250); 0 otherwise
Dyslipidemia DV = 1 for pts with dyslipidemia (ICD 9 CM: 272); 0 otherwise
Osteoporosis DV = 1 for pts with osteoporosis (ICD 9 CM: 733); 0 otherwise
Myocardial infarction DV = 1 for pts with myocardial infarction (ICD 9 CM: 410 + 412); 0 otherwise
Hyperthyroidism DV = 1 for pts with hyperthyroidism (ICD 9 CM: 242); 0 otherwise
Diagnosed year
Before 1988 Reference
Between 1988 and 1992 DV = 1 for diagnosed year between 1988 and 1992, including 1988 and 1992; 0 otherwise
1993 onward DV = 1 for diagnosed year ≥ 1993; 0 otherwise
Year missing DV = 1 for diagnosed year were missing; 0 otherwise
*DV, dummy variable.
†Other races:American Indian,Aleut, Eskimo, and others.
‡Other degrees: GED (general equivalent diploma), high school diploma, and others.
Abbreviation: pts, patients.
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Table 3 Predisposing, enabling, and need characteristics between the two drug groups
Variable AC (N = 7.3 million) BD (N = 3.1 million) Statistic test P value
Predisposing factors
Age
Mean (SD) 61 (16.9) 62 (24.7) Student’s t .373
Race Chi-square .001†
% White (reference) 79 89
% African American 16 9
% Other 5 2
Sex Chi-square .388
% Male 42 40
Education Chi-square .502
% With college degree or higher 15 13
% Other 56 57
% With no degree (reference) 29 30
Employment status Chi-square .865
% Employed 43 42
Marital status Chi-square .007†
% Married 62 73
Enabling factors
Insurance status
% With HMO 38 28 Chi-square .070
% With FFS (reference) 57 67 Chi-square .030*
% Other public 3 3 Chi-square .434
% Uninsured 8 5 Chi-square .131
Annual income ($)
Mean (SD) 20,843 (18,793) 20,256 (20,323)
Median 13,280 14,955
% at < 10,000 (reference) 37 31 Chi-square .386
% at 10,000–14,999 14 19
% at 15,000–29,999 25 27
% at ≥ 30,000 23 23
MSA
Yes (%) 76 72 Chi-square .424
Census region (%) Chi-square .635
Northeast 20 22
South 37 33
West 19 22
Midwest (reference) 25 23
Total out of pocket for 
antihypertensive drugs
Mean (SD) 131 (246.44) 97 (241.11) Student’s t .027*
Median 54 40
Need factors
Perceived health status Chi-square .375
% Excellent/very good 40 34
% Good 32 36
% Fair or poor (reference) 29 30
Perceived mental health status Chi-square .078
% Excellent/very good 61 64
% Good 29 28
% Fair or poor (reference) 10 8
Limitations in daily life
Mean (SD) 0.9 (1.6) 0.8(1.5) Kruskal-Wallis .805
Median 0 0
Comorbidities (%)
Diabetes 18 9 Chi-square .001†
Dyslipidemia 10 17 Chi-square .009†
Osteoporosis 3 3 Chi-square .515
Myocardial infarction 2 3 Chi-square .592
Hyperthyroidism 0.2 0.3 Chi-square .828
Number of comorbidities
Mean (SD) 0.6 (1.0) 0.6 (1.7) Kruskal-Wallis .697
Median
Diagnosed year 0 0 Chi-square .001†
% Before 1988 (reference) 29 41
% Between 1988 and 1992 20 16
% 1993 onward 40 29
% With year missing 12 14
*P < .05.
†P < .01.
Abbreviations:AC,ACEIs or CCBs; BD, diuretics or beta-blockers.
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Table 4 Logistic regression model (dependent variable: selection of diuretics or
beta-blockers)
95% CI
Parameter P value OR Lower Upper
Intercept 0.30 .77 1.34 0.19 9.43
Predisposing factors
Age -0.01 .32
Race
African American -0.55 .035* 0.58 0.35 0.96
Other -1.24 .13 0.29 0.06 1.46
White (reference)
Sex
Male -0.28 .16 0.76 0.51 1.11
Female (reference)
Education status
College degree or higher -0.20 .58 0.82 0.41 1.64
Other 0.02 .94 1.02 0.63 1.64
No degree (reference)
Employment status
Employed -0.05 .88 0.96 0.54 1.69
Not employed (reference)
Marital status
Married 0.65 .001† 1.92 1.30 2.84
Not married (Reference)
Enabling factors
Insurance status
HMO -0.70 .002† 0.50 0.32 0.77
Uninsured -0.31 .39 0.73 0.36 1.49
Other public -0.28 .64 0.76 0.24 2.45
FFS (reference)
Annual income ($)
<10,000 (reference)
10,000–14,999 0.53 .09 1.70 0.92 3.11
15,000–29,999 0.25 .38 1.28 0.74 2.22
≥30,000 0.12 .73 1.13 0.57 2.23
MSA
Yes -0.06 .76 0.94 0.62 1.43
No (reference)
Census region
Northeast 0.25 .34 1.28 0.77 2.13
South 0.08 .74 1.08 0.67 1.74
West 0.46 .09 1.58 0.93 2.68
Midwest (reference)
Total out of pocket for 
antihypertensive drug -0.002 .013*
Need factors
Physical health status
Excellent/very good -0.77 .005† 0.47 0.28 0.79
Good -0.25 .30 0.78 0.48 1.25
Fair/poor (reference)
Mental health status
Excellent/very good 0.48 .24 1.61 0.73 3.55
Good 0.28 .51 1.32 0.58 3.04
Fair/poor (reference)
Limitations in daily life -0.01 .90 0.99 0.87 1.14
Comorbidities
Diabetes -1.07 .000† 0.34 0.20 0.59
Dyslipidemia 0.36 .20 1.44 0.82 2.51
Osteoporosis 0.06 .93 1.06 0.27 4.21
Myocardial infarction 0.18 .74 1.19 0.43 3.33
Hyperthyroidism 1.08 .30 2.94 0.38 22.74
None above (reference)
Diagnosed year
Before 1988 (reference)
Between 1988 and 1992 -0.72 .007† 0.49 0.29 0.82
1993 onward -0.88 .001† 0.42 0.25 0.69
Year missing -0.05 .89 0.95 0.48 1.92
*P < .05.
†P < .01.
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Patients diagnosed from 1988 to 1992 and after
1993 were less likely to use diuretics or beta-
blockers (OR 0.486, 95% CI 0.289–0.817, P < .01;
OR 0.416, 95% CI 0.251–0.691, P < .01), com-
pared to patients who were diagnosed with hyper-
tension before 1988. Patients with the missing
diagnosed year did not show statistical signiﬁcance.
Discussion
This study investigated the insurance impact on the
patterns of antihypertensive drug use for the non-
institutionalized US adult population with essential
hypertension. In the study population, the number
of patients using an ACEI or CCB (7.3 million) was
more than twice as high as the number of patients
with diuretics or beta-blockers (3.1 million). This
result was consistent with national trends [5].
Our study indicated that patients with HMO
insurance were more likely to use ACEIs or CCBs
compared to patients with FFS insurance after 
controlling for all other potential confounders. This
ﬁnding, while consistent with the report of Jerome
and colleagues [39] that physicians used either
CCBs or ACEIs as initial monotherapy for the
majority of cases in an open-panel HMO, provides
nationally population-based evidence suggesting
that HMO patients were less likely to be treated in
the management of essential hypertension following
the JNC guidelines. This is contrary to a popular
view that HMOs in general are more likely to exer-
cise management controls to encourage prescribing
that is consistent with established national guide-
lines, particularly if the recommended therapy also
represents the lower cost alternative.
One possible explanation for this ﬁnding is that
most patients in the study might have been enrolled
in open-panel HMOs with relatively weak controls
over prescribing [40]. Another possible explanation
might be that HMO patients, in contrast to FFS
patients, might have had a prescription drug insur-
ance beneﬁt with a ﬁxed copayment that did not
differ according to the type of antihypertensive drug
prescribed. Thus, the patients with HMO coverage
had no preference for encouraging their physician
to select more cost-effective antihypertensive drugs.
In contrast, patients with FFS coverage appeared to
have a stronger preference for selecting lower cost
drugs such as diuretics or beta-blockers.
Our study indicated that the higher the amount
of total out-of-pocket costs for antihypertensive
drugs, the more use of ACEIs or CCBs. This might
be a consequence of purchasing higher cost of
ACEIs or CCBs compared to diuretics or beta-
blockers [18]. It is possible that physicians may be
more likely to prescribe more expensive medica-
tions (ACEIs and CCBs) to patients in higher
socioeconomic classes. However, our result did not
show a statistical signiﬁcance between the patterns
of antihypertensive drug use and annual income in
the model.
Nevertheless, it is possible that the higher
amount of out-of-pocket payment is an indication
of the patient self-revealed preference in the use of
ACEIs and CCBs in light of their lower side effects.
In the study by Croog and colleagues [24], patients
taking captopril (ACEI) reported fewer side effects
and less sexual dysfunction than those taking 
propranolol (beta-blocker). Another randomized
controlled clinical trial [23] showed that sexual
function was signiﬁcantly worsened with propra-
nolol. Fletcher [25] reported that diuretics also pro-
duced erectile dysfunction. Interestingly, our study
indicated that married patients were more likely to
be prescribed and use beta-blockers or diuretics
compared to nonmarried patients.
We found that African Americans were less likely
to use beta-blockers and diuretics than whites. JNC
IV–VI guidelines suggest that African Americans
may not be as responsive to beta-blockers or ACEIs.
JNC VI also notes that, because of a greater preva-
lence of stage 3 hypertension, African Americans
may be candidates for multiple drug therapy. This
may explain a greater propensity for African Amer-
icans to use CCBs or ACEIs. Since we grouped the
four primary drugs differently, we could not directly
measure whether or not prescribing was consistent
with these guidelines.
The results also showed that patients in the excel-
lent or very good perceived health status were more
likely to use ACEIs or CCBs, compared to patients
in the fair or poor perceived health status. Because
patients reported perceived health status, it is pos-
sible that patients experiencing adverse effects (such
as depression) from their prescribed antihyperten-
sive drug (such as a nonselective beta-blocker)
might have reported lower health status.
JNC VI [4] guidelines suggest that in patients
with certain comorbidities, some antihypertensive
drugs should be avoided or used with caution. For
example, according to the JNC VI [4], for dyslipi-
demia, diuretics or beta-blockers may elevate lipid
levels. For osteoporosis, thiazide diuretics may have
favorable effects; for myocardial infarction, CCBs
may be preferred; and for hyperthyroidism, beta-
blockers may be preferred. However, our ﬁndings
did not show signiﬁcant drug use preference for
hypertensive patients with these comorbidities. As
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for patients with diabetes, we did ﬁnd less frequent
use of beta-blockers and diuretics, which is gener-
ally consistent with guidelines. Physicians should
consider enhanced individualization of antihyper-
tensive drug therapy in the future.
We conducted a subanalysis of our data based on
the version of the JNC guidelines then in effect. We
found that patients diagnosed from 1988 to 1992
were more likely to use ACEIs or CCBs, compared
to patients who were diagnosed before 1988. This
result is consistent with the guidelines of the JNC
IV, which recommended four classes of antihyper-
tensive drugs. The patterns of use continued after
1993, however, when the JNC V guidelines indi-
cated a preference for diuretics and beta-blockers.
Thus, the guidelines seemingly had little effect on
the patterns of antihypertensive drug use, a ﬁnding
that was consistent with the study by Siegel and
Lopez [21]. One possible reason is that physicians
may be reluctant to switch drug therapy because of
already well-controlled blood pressure. Another
possible reason may be that prescribing patterns
were inﬂuenced by pharmaceutical manufacturer
promotional activities, which generally were more
focused on patented drugs in the ACEI and CCB
group. Because of the limitations of the data set, we
were not able to quantify or distinguish between the
impact of these factors.
Conclusion
In light of the sharp contrast between prescribing
patterns in practice and the JNC guidelines for 
the treatment of uncomplicated hypertension, this
study investigated the insurance impact on the
choice of alternative antihypertensive drugs based
on a nationally representative sample of population
derived from the 1996 MEPS data. After control-
ling for other observed confounding factors in the
context of Anderson health utilization model, this
study found that insurance type had a statistically
signiﬁcant impact on the determination of antihy-
pertensive drug choice. Contrary to a popular hypo-
thetical view, patients with HMO insurance 
had proportionately less use of diuretics and beta-
blockers compared to FFS patients. While further
study is needed to explain why it was so, this ﬁnding
does suggest that insurance coverage is an impor-
tant determinant of drug choice and use in the treat-
ment of hypertension.
A methodologic strength of this study lies in the
fact that the MEPS provides representative esti-
mates of health-care use at the national level over
time, for a sample of a noninstitutionalized US pop-
ulation, while most previous related studies were
restricted to elderly or poor people [30,32]. In addi-
tion, we used the multivariate approach to control
confounders in the context of Anderson model for
antihypertensive drug use.
This study has several limitations that should 
be noted. First, the MEPS design is a stratiﬁed 
sampling based on demographic characteristics;
therefore, extrapolation of the results for the insti-
tutionalized US adult population such as nursing
home patients with essential hypertension should be
done with caution.
Second, this is a cross-sectional study design.
Because the 1996 MEPS data do not contain the
time of each prescription, the switch of drug treat-
ment before and in 1996 could not be considered
in the study design. The database was not sufﬁ-
ciently large for us to consider initial prescribing
decisions occurring during this target year, although
we did have available the year of ﬁrst diagnosis 
of hypertension. We could not examine switches
among the four antihypertensive drugs due to non-
response or to side effects.
Third, there is no information available in the
MEPS 1996 about the prescriber (e.g., age, physi-
cian type—resident, primary care physician, or 
specialist), which might inﬂuence the prescribing
patterns of antihypertensive drugs. In addition,
while we tried to control for all important comor-
bidities related to antihypertensive drug use, some
conditions were too few or nonexistent to include
such as congestive heart failure and left ventricular
hypertrophy.
Fourth, the MEPS data set did not provide
speciﬁcs concerning the nature of the pharmacy
beneﬁt, if any. However, our model included four
insurance models, including HMO versus FFS.
Assuming that HMOs are more likely to have a
pharmacy beneﬁt, our model should have captured
some part of the pharmacy beneﬁt impact.
Finally, owing to the potential complexity of
study design, we had to exclude some patients with
other medications for essential hypertension while
investigating the utilization pattern of the four most
commonly used antihypertensive drug classes.
Although we did not explicitly examine the differ-
ences, we believe that excluded patients might have
had more severe hypertension or other related car-
diovascular conditions.
Further research is needed to discern the under-
lying reason why an association was found between
insurance type and the patterns of antihypertensive
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drug use. Another question is whether or not insur-
ance type also affected longer-term costs of 
care, clinical outcomes, or quality of life of patients
with hypertension. Outcomes research based on a
national population sample may provide better
insight into the underlying reasons for the discrep-
ancy between medical practice and the JNC recom-
mendations. Moreover, such outcomes research
data may also offer stronger grounds for the JNC
guidelines in an attempt to increase the compliance
of both patients and health-care providers, espe-
cially in managed care organizations.
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